Its Stock Has Paid Off Big Time For Agile Therapeutics Inc.

Agile Therapeutics Inc. (NASDAQ: AGRX) stock jumped 5.86% on Monday to $0.30 against a previous-day closing price of $0.28. With 0.92 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.9 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.3040 whereas the lowest price it dropped to was $0.2850. The 52-week range on AGRX shows that it touched its highest point at $15.60 and its lowest point at $0.17 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at 1.04.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AGRX was up-trending over the past week, with a rise of 2.21%, but this was up by 69.37% over a month. Three-month performance surged to 12.06% while six-month performance fell -45.16%. The stock lost -97.79% in the past year, while it has gained 30.57% so far this year. A look at the trailing 12-month EPS for AGRX yields -14.93 with Next year EPS estimates of -0.67. For the next quarter, that number is -0.23. This implies an EPS growth rate of -26.00% for this year and 71.10% for next year.

Float and Shares Shorts:

At present, 37.00 million AGRX shares are outstanding with a float of 36.81 million shares on hand for trading. On Oct 13, 2022, short shares totaled 1.22 million, which was 3.14% higher than short shares on Sep 14, 2022. In addition to Mr. Alfred F. Altomari as the firm’s Chairman & CEO, Mr. Geoffrey P. Gilmore serves as its Sr. VP, Chief Admin. Officer & Corp. Sec.

Institutional Ownership:

Through their ownership of 0.55% of AGRX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 4.71% of AGRX, in contrast to 0.93% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in AGRX with 1.31% of the stake, Perceptive Advisors LLC holds 532,361 shares worth 532,361. A second-largest stockholder of AGRX, LPL Financial LLC, holds 411,506 shares, controlling over 1.01% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in AGRX, holding 303,741 shares or 0.75% stake. With a 0.51% stake in AGRX, the Fidelity Extended Market Index Fu is the largest stakeholder. A total of 208,839 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.19% of AGRX stock, is the second-largest Mutual Fund holder. It holds 76,860 shares valued at 17447.0. Diamond holds 0.15% of the stake in AGRX, owning 60,050 shares worth 13631.0.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AGRX since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AGRX analysts setting a high price target of $3.00 and a low target of $1.00, the average target price over the next 12 months is $2.00. Based on these targets, AGRX could surge 900.0% to reach the target high and rise by 233.33% to reach the target low. Reaching the average price target will result in a growth of 566.67% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AGRX will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of -$2.42 being high and -$2.50 being low. For AGRX, this leads to a yearly average estimate of -$2.46. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Agile Therapeutics Inc. surprised analysts by -$0.09 when it reported -$0.53 EPS against a consensus estimate of -$0.44. The surprise factor in the prior quarter was $0.99. Based on analyst estimates, the high estimate for the next quarter is -$0.21 and the low estimate is -$0.23. The average estimate for the next quarter is thus -$0.22.

Summary of Insider Activity:

Insiders traded AGRX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 54,690 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *